Thiotriazolin effectiveness in complex treatment of patients with post-COVID syndrome

The aim of this work is to evaluate the complex therapeutic effect of Thiotriazolin (anticoagulant, antiplatelet, metabolitotropic, endothelioprotective activity) in patients with post-COVID syndrome in comparison with basic therapy. Materials and methods. The studies involved 30 patients aged between 30 to 60 years with post-COVID syndrome. Of these, 15 persons received basic therapy (antibiotics, anticoagulants, acetylsalicylic acid), and other 15 patients received Thiotriazolin in the form of 200 mg tablets twice a day for 30 days against the background of basic therapy. Inclusion criteria were a positive PCR test for COVID-19; if the PCR test was negative, then the patients were enrolled based on the presence of IgM COVID-19 or IgG COVID-19 (with X-ray confirmed pneumonia). The rate of lung damage is up to 45 %. The patients had the following comorbidities: diabetes mellitus in the stage of compensation, arterial hypertension, ischemic heart disease without heart failure. The results of the study were calculated using the standard statistical package Statistica for Windows 13 (StatSoft Inc., № JPZ804I382130ARCN10-J), аs well as SPSS 16.0, Microsoft Office Excel 2003. Results. The inclusion of Thiotriazolin in the complex basic therapy of post-COVID syndrome led to a significant increase in the effectiveness of basic endothelioprotective, anticoagulant and antiaggregatory therapy and contributed to the prevention of thrombus formation. The administration of Thiotriazolin led to a significant improvement in general clinical parameters in patients with post-COVID syndrome – complaints of tachycardia disappeared, blood pressure was stabilized (without additional correction with antihypertensive drugs), weakness and increased fatigue disappeared. Saturation in 14 (93.4 %) patients increased to 97–98 %. In the control group only 7 (46.7 %) of 15 patients had oxygen saturation at 97–98 % level. Conclusions. The introduction of the drug Thiotriazolin in the form of 200 mg tablets twice a day for 30 days into the complex basic therapy of post-COVID syndrome leads to a significant increase in the basic endothelioprotective, antiaggregatory and anticoagulant therapy and contributes to the prevention of thrombus formation against the background of improving the state of the myocardium and vascular endothelium.

Modern biomarker cardiotrophin-1 in the diagnosis of myocardial diastolic function in men with essential hypertension

Annotation. The aim of the study was to improve the diagnosis of myocardial diastolic function in men with essential hypertension and chronic heart failure with different variants of the cardiotrophin-1 gene. 100 people aged 40–60 were examined: 50 men with asymptomatic essential hypertension and 50 men with essential hypertension complicated by chronic heart failure. Genotyping of the cardiotrophin-1 gene was performed by polymerase chain reaction. Determination of the concentration of cardiotrophin-1 was performed by enzyme-linked immunosorbent assay. Structural and functional parameters of the myocardium were evaluated using ultrasound of the heart. Mathematical processing of the material was performed on a personal computer using the standard statistical package SPSS 10. It was found that in persons with essential hypertension and chronic heart failure, carriers of the GA + AA variant of the cardiotrophin-1 gene (rs8046707) have significantly higher plasma peptide levels with diastolic dysfunction (p <0.05).

Credibility Theory and Generalized Linear Models

This paper shows how credibility theory can be encompassed within the theory of Hierarchical Generalized Linear Models. It is shown that credibility estimates are obtained by including random effects in the model. The framework of Hierarchical Generalized Linear Models allows a more extensive range of models to be used than straightforward credibility theory. The model fitting and testing procedures can be carried out using a standard statistical package. Thus, the paper contributes a further range of models which may be useful in a wide range of actuarial applications, including premium rating and claims reserving.